BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine Sells 4,292 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Hannah Valantine sold 4,292 shares of the stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $40.00, for a total transaction of $171,680.00. Following the transaction, the director now owns 1,764 shares of the company's stock, valued at $70,560. This represents a 70.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

BridgeBio Pharma Stock Up 1.2%

Shares of NASDAQ BBIO traded up $0.46 during midday trading on Thursday, reaching $39.51. The company had a trading volume of 885,373 shares, compared to its average volume of 3,003,417. The stock has a market cap of $7.50 billion, a PE ratio of -13.86 and a beta of 1.10. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $40.40. The firm's fifty day moving average price is $34.92 and its 200-day moving average price is $32.91.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to the consensus estimate of $57.14 million. During the same quarter in the previous year, the firm posted ($0.20) EPS. The business's revenue for the quarter was down 44.8% compared to the same quarter last year. As a group, equities research analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BBIO shares. Scotiabank lifted their price target on BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald reissued an "overweight" rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. Redburn Atlantic started coverage on shares of BridgeBio Pharma in a research report on Monday, March 31st. They issued a "buy" rating and a $50.00 price objective on the stock. HC Wainwright raised their price objective on shares of BridgeBio Pharma from $53.00 to $56.00 and gave the company a "buy" rating in a research report on Monday. Finally, Piper Sandler upped their price objective on BridgeBio Pharma from $46.00 to $63.00 and gave the stock an "overweight" rating in a report on Wednesday, April 30th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $57.36.

Institutional Investors Weigh In On BridgeBio Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BBIO. Steward Partners Investment Advisory LLC grew its holdings in BridgeBio Pharma by 85.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after acquiring an additional 472 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of BridgeBio Pharma by 71.0% in the first quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after purchasing an additional 382 shares during the last quarter. Jones Financial Companies Lllp bought a new stake in shares of BridgeBio Pharma in the first quarter worth about $35,000. Itau Unibanco Holding S.A. purchased a new position in BridgeBio Pharma during the 4th quarter valued at about $41,000. Finally, Sterling Capital Management LLC raised its position in BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after purchasing an additional 1,514 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.